Design: Retrospective claims cohort, inverse probability weighted cumulative incidence
Population: 467,721 US women aged 50 or over with an incident clinical fracture, 2012–2021
Primary outcome: Subsequent fracture at least 90 days after the index fracture
Effect: 24-month subsequent fracture 19.4% (spine 27.8%, pelvis 24.2%); treatment initiation 17.5%

This retrospective US claims cohort identified 467,721 women aged 50 or over with a new clinical fracture between 2012 and 2021, median age 76, and followed them to the end of 2023.

By 24 months, 19.4% had another fracture. Risk was highest after spine (27.8%) and pelvic (24.2%) fractures, and rose with age and with a prior osteoporosis diagnosis. Only 17.5% began any osteoporosis drug by 24 months, and almost two-thirds of those who did started in the first six months — the window after which treatment rarely begins.

The fracture admission is where this gap is decided. Many of these women pass through medical wards, often for a fall, delirium or a medical problem alongside the fracture, and leave without a plan for bone health. Claims data cannot show why treatment was not started, and US practice may differ from Indian practice, but the imminent-risk window is a biological fact, not a feature of one health system.

Treat a low-trauma fracture in a woman over 50 as a diagnosis of osteoporosis until shown otherwise.
Start or arrange bone-protective treatment before discharge, or name who will do it.
Prioritise women with spine or pelvic fractures; one in four fractured again within two years.
Check vitamin D, calcium and kidney function before choosing an agent.
Write the bone plan explicitly in the discharge summary for the primary care team.

Why it matters

The fracture admission is the best chance to prevent the next fracture, and it is usually missed.

The statistics, in plain English

These are cumulative risks: 19.4% means about one in five women had a second fracture within two years. They describe what happened, not what treatment would have prevented, because the study did not compare treated and untreated women.